The authors regret that an error occurred in Table 6 of the above paper. The ARR for Kampman et al (2012) was displayed as 5.02 with a NNT of 19.91; however, it should have been an ARR of −5.02 with a NNTH (i.e. NNT with a negative outcome or harm) of 19.91.
This does not change any of the other conclusions or analyses in the paper.
The authors would like to apologise for any inconvenience caused.
Published online: July 18, 2014
© 2014 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- The case for vitamin D supplementation in multiple sclerosisMultiple Sclerosis and Related DisordersVol. 2Issue 4
- PreviewGiven that vitamin D has a role in immunomodulation, and its levels appear to correlate with the development of Multiple Sclerosis (MS), it is conceivable that vitamin D may also influence disease activity in MS patients. In this regard, we conducted a systematic review investigating the evidence for: (1) the role of vitamin D in disease activity in MS, and (2) the therapeutic supplementation of vitamin D in MS.